Gene synthesis is a synthetic biology technique used in the laboratory to create artificial genes. In contrast to molecular cloning and polymerase chain reaction, this method uses solid-phase DNA synthesis (PCR). Gene synthesis is utilized for molecular cloning, the production of fusion proteins, and attaining sufficient protein expression levels. Compared to conventional molecular cloning techniques, the gene synthesis service provides unparalleled customization from top to bottom while saving time and money. Gene synthesis is the chemical in vitro synthesis of double-stranded DNA molecules. It is a biotechnology tool that has a significant impact on synthetic biology.
In molecular biology and gene therapy, the development and application of numerous cutting-edge gene-editing techniques for editing represent a significant advancement. Consequently, significant progress has been made in developing gene therapy for use in molecular biology. Recent technological advancements have produced well-designed goods and services, such as molecular separation, gene synthesis on microchips, and protein purification, which have contributed to the expansion of life science research. Gene synthesis has been acknowledged as an efficient and cost-effective alternative to conventional cloning and mutagenesis techniques. These dependable and efficient solutions in developed nations drive federal funding for various academic research projects and the market.
One of the factors that will positively impact the gene synthesis market is the rising public demand for targeted and personalized medicine. In addition, increasing government, private, and public investment in synthetic biology is anticipated to speed up the global gene synthesis market and create lucrative business opportunities for key players in the coming years.
North America is the largest global gene synthesis market shareholder due to significant players and government initiatives in training and implementing synthetic biology programs. The increasing use of gene editing and synthesis-related techniques by drug and diagnostic developers in the United States fosters regional market expansion. Additionally, regulatory approval and commercialization of synthetic gene products in the region have contributed to the expansion of the market.
- The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033).
- Based on the method, the market is divided into solid-phase, chip-based, and PCR-based enzyme synthesis. The solid-phase segment accounts for the largest revenue share due to the highest adoption rate over the past few years.
- Based on service, the market is categorized into antibody DNA synthesis, viral DNA synthesis, and others. The antibody DNA synthesis segment is the most dominant due to the large number of market participants providing services for antibody DNA synthesis.
- Based on application, the market is bifurcated into gene and cell therapy development, vaccine development, disease diagnosis, and others. The development of gene and cell therapies accounted for the largest revenue share
- Based on end-user, the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations. The academic and governmental research institutes segment is anticipated to dominate the market.
- North America is the largest global gene synthesis market shareholder due to significant players and government initiatives in training and implementing synthetic biology programs.
- GenScript
- Brooks Automation, Inc. (GENEWIZ)
- Boster Biological Technology
- Twist Bioscience
- ProteoGenix
- Biomatik
- ProMab Biotechnologies, Inc.
- Thermo Fisher Scientific, Inc.
- Integrated DNA Technologies, Inc.
- OriGene Technologies, Inc.
- June 2022- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ildong Pharmaceutical announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology.
- July 2022- Twist Bioscience Opened New Twist Boston Location to Expand Antibody Discovery Capacity. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the opening of its new Twist Boston location in Quincy, Massachusetts.
- By Method
- Solid-phase Synthesis
- Chip-based Synthesis
- PCR-based Enzyme Synthesis
- By Service
- Antibody DNA Synthesis
- Viral DNA Synthesis
- Others
- By Application
- Gene and Cell Therapy Development
- Vaccine Development
- Disease Diagnosis
- Others
- By End-User
- Biotechnology and Pharmaceutical Companies
- Academic and Government Research Institutes
- Contract Research Organizations
- By Regions
- North America
- Europe
- Asia-Pacific
- LAMEA